Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study

U. Jaakkola, J. Kallio, R.J. Heine, M.G.A.A.M. Nijpels, L.M. Hart, J.A. Maassen, L.M. Bouter, C.D.A. Stehouwer, J.M. Dekker

Research output: Contribution to journalArticleAcademicpeer-review

38 Downloads (Pure)

Abstract

The leucine7 to proline7 (Leu7Pro) polymorphism in preproneuropeptide Y (preproNPY) has been associated with accelerated atherosclerosis and type II diabetes, both of which are obesity-related diseases. The current study evaluated the impact of obesity on the disease risk linked to the Leu7Pro polymorphism of preproNPY in 393 elderly subjects. In 6 years follow-up, the polymorphism alone did not change the risk for abnormal glucose regulation, while obesity was associated with a significant 3-fold risk (odds ratio (OR) 2.95; 95% confidence interval (CI) 1.81-4.81, P
Original languageEnglish
Pages (from-to)150-152
Number of pages3
JournalEuropean Journal of Clinical Nutrition
Volume63
Issue number1
DOIs
Publication statusPublished - 2009

Cite this

@article{93338e5067a54a19a22201d3ef070460,
title = "Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study",
abstract = "The leucine7 to proline7 (Leu7Pro) polymorphism in preproneuropeptide Y (preproNPY) has been associated with accelerated atherosclerosis and type II diabetes, both of which are obesity-related diseases. The current study evaluated the impact of obesity on the disease risk linked to the Leu7Pro polymorphism of preproNPY in 393 elderly subjects. In 6 years follow-up, the polymorphism alone did not change the risk for abnormal glucose regulation, while obesity was associated with a significant 3-fold risk (odds ratio (OR) 2.95; 95{\%} confidence interval (CI) 1.81-4.81, P",
author = "U. Jaakkola and J. Kallio and R.J. Heine and M.G.A.A.M. Nijpels and L.M. Hart and J.A. Maassen and L.M. Bouter and C.D.A. Stehouwer and J.M. Dekker",
year = "2009",
doi = "10.1038/sj.ejcn.1602964",
language = "English",
volume = "63",
pages = "150--152",
journal = "European Journal of Clinical Nutrition",
issn = "0954-3007",
publisher = "Nature Publishing Group",
number = "1",

}

Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study. / Jaakkola, U.; Kallio, J.; Heine, R.J.; Nijpels, M.G.A.A.M.; Hart, L.M.; Maassen, J.A.; Bouter, L.M.; Stehouwer, C.D.A.; Dekker, J.M.

In: European Journal of Clinical Nutrition, Vol. 63, No. 1, 2009, p. 150-152.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study

AU - Jaakkola, U.

AU - Kallio, J.

AU - Heine, R.J.

AU - Nijpels, M.G.A.A.M.

AU - Hart, L.M.

AU - Maassen, J.A.

AU - Bouter, L.M.

AU - Stehouwer, C.D.A.

AU - Dekker, J.M.

PY - 2009

Y1 - 2009

N2 - The leucine7 to proline7 (Leu7Pro) polymorphism in preproneuropeptide Y (preproNPY) has been associated with accelerated atherosclerosis and type II diabetes, both of which are obesity-related diseases. The current study evaluated the impact of obesity on the disease risk linked to the Leu7Pro polymorphism of preproNPY in 393 elderly subjects. In 6 years follow-up, the polymorphism alone did not change the risk for abnormal glucose regulation, while obesity was associated with a significant 3-fold risk (odds ratio (OR) 2.95; 95% confidence interval (CI) 1.81-4.81, P

AB - The leucine7 to proline7 (Leu7Pro) polymorphism in preproneuropeptide Y (preproNPY) has been associated with accelerated atherosclerosis and type II diabetes, both of which are obesity-related diseases. The current study evaluated the impact of obesity on the disease risk linked to the Leu7Pro polymorphism of preproNPY in 393 elderly subjects. In 6 years follow-up, the polymorphism alone did not change the risk for abnormal glucose regulation, while obesity was associated with a significant 3-fold risk (odds ratio (OR) 2.95; 95% confidence interval (CI) 1.81-4.81, P

U2 - 10.1038/sj.ejcn.1602964

DO - 10.1038/sj.ejcn.1602964

M3 - Article

VL - 63

SP - 150

EP - 152

JO - European Journal of Clinical Nutrition

JF - European Journal of Clinical Nutrition

SN - 0954-3007

IS - 1

ER -